Quantifying Preferences for CAR ‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma
Cancer Medicine · 2025
DOI: 10.1002/cam4.71072 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jessie Sutphin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Patient Preference, Standard of Care, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development.
Abstract (Originalsprache)
Background
CAR‐T therapy is approved for the treatment of relapsed refractory multiple myeloma (MM) and is being studied for newly diagnosed MM (NDMM). The use of novel therapies in early‐line MM raises questions on the acceptability of upfront risks in exchange for extended relapse‐free periods without the treatment burden and limitations on daily activities associated with maintenance therapy.
Methods
A discrete‐choice experiment was designed to elicit adults' preferences for hypothetical NDMM treatments. Benefits included time to relapse and reduction of treatment impact on daily activities. Severe adverse events were included to better understand patient preferences for rare but significant events.
Results
On average, extending the time to relapse from 3 years (with moderate limitations on daily activities) to 5 years (without limitations) was three times more important than avoiding a 20% risk of hospitalization due to severe ICANS/CRS. Analysis revealed three latent preference classes: a benefit–risk trading class (65%), a class (28%) unwilling to accept increases in short‐term treatment‐related mortality, and a class (7%) that provided statistically uninformative data. For the trading class, for two additional relapse‐free years with minor limitations, all else equal, patients would accept up to a 30% risk of severe ICANS/CRS‐related hospitalization along with 0% risk of treatment‐related mortality. Alternatively, they would accept up to an 8% risk of treatment‐related mortality with a 0% risk of severe ICANS/CRS‐related hospitalization, or various combinations of lower AE risks.
Conclusion
These results reveal preference heterogeneity among MM patients and the importance of effective communication about the benefits and risks of novel therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Janssen Research and Development, Raritan, New Jersey, USA.
ORCID-Profile: Jessie Sutphin, Thomas W LeBlanc, Laura Hester
Förderung
- Janssen Research and Development
Zitieren
APA
Sutphin, J., LeBlanc, T. W., Janssen, E., Hester, L., Wallace, M. J., Johnson, F. R., & Reed, S. D. (2025). Quantifying Preferences for CAR ‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma. Cancer Medicine. https://doi.org/10.1002/cam4.71072
Vancouver
Sutphin J, LeBlanc TW, Janssen E, Hester L, Wallace MJ, Johnson FR, et al. Quantifying Preferences for CAR ‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma. Cancer Medicine. 2025. doi:10.1002/cam4.71072
BibTeX
@article{Sutphin2025,
author = {Sutphin, Jessie and LeBlanc, Thomas W and Janssen, Ellen and Hester, Laura and Wallace, Matthew J and Johnson, F Reed and Reed, Shelby D},
title = {Quantifying Preferences for CAR ‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71072}
}
EUVIMED